Listed New Zealand and Australian childcare and education centre operator Evolve Education Group
Limited (ASX/NZX: EVO) is pleased to confirm to shareholders:
1 Confirmation of Year End Date: The financial year end date for EVO is 31 March. EVO
expects to announce results for the financial year ended 31 March 2020 on 25 May
2020.
2 Coronavirus Impact: EVO wishes to advise that has been no material impact (either
operational or financial) on any EVO centre in NZ or Australia nor in aggregate terms.
Consequently, EVO guidance issued to the market in November 2019 for the year
ended 31 March 2020 remains intact.
3 Guidance Update: EVO wishes to reaffirm the guidance given on 28 November 2019.
Specifically, EVO anticipates EBITDA of no less than $15m for the CY20 – that is, for
the period commencing 1 January 2020 and ending 31 December 2020.
Evolve Education Group Managing Director, Chris Scott said “The Group continues to trade in line
with guidance earnings provided and continues to progress initiatives as outlined in the half year
results announcement made on 28 November 2019“.
- Forums
- ASX - By Stock
- GEM
- GEM buy?
GEM buy?, page-59
-
- There are more pages in this discussion • 338 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GEM (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.36 |
Change
0.015(1.12%) |
Mkt cap ! $1.094B |
Open | High | Low | Value | Volume |
$1.35 | $1.38 | $1.34 | $2.146M | 1.581M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 72 | $1.50 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.23 | 40236 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
16 | 32795 | 1.355 |
9 | 30736 | 1.350 |
13 | 93570 | 1.345 |
10 | 110846 | 1.340 |
2 | 10808 | 1.335 |
Price($) | Vol. | No. |
---|---|---|
1.360 | 5677 | 7 |
1.365 | 36251 | 14 |
1.370 | 32335 | 10 |
1.375 | 59016 | 10 |
1.380 | 48418 | 11 |
Last trade - 15.59pm 13/11/2024 (20 minute delay) ? |
Featured News
GEM (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online